Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Esteva on Trastuzumab Biosimilar in Patients With HER2+ Breast Cancer

Francisco J. Esteva, MD, PhD
Published: Thursday, Jul 07, 2016



Francisco J. Esteva, MD, PhD, medical oncology, New York Langone Medical Center, discusses a randomized phase III study of the biosimilar version of trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer.

Researchers compared the efficacy and safety of the biosimilar version of trastuzumab, MYL-1401O, plus a taxane with trastuzumab plus a taxane in approximately 500 patients. Results showed that the biosimilar and trastuzumab were similar in both aspects.

In the study, MYL-1401O demonstrated an overall response rate (ORR) of 69.6% among women who received the biosimilar in combination with a taxane compared with a 64% ORR for patients who received trastuzumab plus a taxane. Serious adverse events occurred in 38% of patients in the biosimilar arm compared with 36% in the trastuzumab arm.


Francisco J. Esteva, MD, PhD, medical oncology, New York Langone Medical Center, discusses a randomized phase III study of the biosimilar version of trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer.

Researchers compared the efficacy and safety of the biosimilar version of trastuzumab, MYL-1401O, plus a taxane with trastuzumab plus a taxane in approximately 500 patients. Results showed that the biosimilar and trastuzumab were similar in both aspects.

In the study, MYL-1401O demonstrated an overall response rate (ORR) of 69.6% among women who received the biosimilar in combination with a taxane compared with a 64% ORR for patients who received trastuzumab plus a taxane. Serious adverse events occurred in 38% of patients in the biosimilar arm compared with 36% in the trastuzumab arm.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advent of Oncology Monoclonal Antibody Biosimilars ‒ A European Perspective OnlineNov 30, 20183.0
Community Practice Connections™: Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic MalignanciesMar 08, 20193.0
Publication Bottom Border
Border Publication
x